Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

Completed · Not applicable · Has a placebo group

Conditions studied: Dermatologic Complications, Malignant Neoplasm, Pain

In brief

This clinical trial studies menadione topical lotion in treating skin discomfort and psychological distress in patients with cancer receiving panitumumab, erlotinib hydrochloride, or cetuximab. Menadione topical lotion may prevent rash or other skin discomfort and help alleviate psychological distress and pain in patients receiving treatment with panitumumab, erlotinib hydrochloride, or cetuximab

Key facts

Study ID

NCT01393821

Run by

Mayo Clinic

People needed

27

Starts

2012-01-23

Expected to finish

2018-07-14

Last updated by the study team

2025-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older.
• Patient scheduled to start an epidermal growth factor receptor inhibitor (must be one of these three: panitumumab, erlotinib, cetuximab) within the next 3 days or patient has already started the epidermal growth factor receptor inhibitor but has not been on it for longer than 3 days and has no signs or symptoms potentially suggestive of EGFR inhibitor toxicity.
• Ability to reliably apply Menadione Topical Lotion / placebo twice a day to the face.
• Ability to complete questionnaire(s) by themselves or with assistance.
• Negative pregnancy test (serum or urine) done ≤ 7 days prior to registration, for women of childbearing potential only.
• Willing to have photographs taken to assess rash.

You may not qualify if…

• Any active facial and/or chest rash, including adult acne, at the time of randomization.
• Cutaneous metastases, skin cancer, or a history of precancerous skin lesions involving the face and/or chest.
• Use of topical corticosteroids on the face and/or chest at the time of study entry or their anticipated use in the next 8 weeks.
• Any type of ongoing therapy for rash.
• Any of the following:
• Pregnant women
• Nursing women
• Men or women of childbearing potential who are unwilling to employ adequate contraception since this study involves agents that have known genotoxic, mutagenic and teratogenic effects
• Use of any antibiotic at the time of study or their anticipated use in the 8 weeks immediately following study enrollment.

Where it is running

• Mayo Clinic Campus in Arizona — Phoenix, Arizona, United States
• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.